Forgot Password?
Return to Course Listing

CME: Hitting management strategies of metastatic nasopharyngeal carcinoma on the nose

Activity Description / Statement of Need:

In this online, self-learning activity:

Nasopharyngeal carcinoma (NPC) is a rare form of head and neck cancer, with 133,000-176,000 new cases diagnosed worldwide each year. Although relatively uncommon in the United States, NPC has been shown to be endemic in certain geographic regions, such as southern China, Southeast Asia, and North Africa. Several risk factors for NPC have been identified, including consumption of salted fish, alcohol use, wood dust exposure, and plasma Epstein–Barr virus (EBV) positivity.

Target Audience:

HCPs including: medical oncologists; radiation oncologists; otolaryngologists, physician assistants, nurse practitioners, or pharmacists specializing in oncology; and any other clinicians who are involved or interested in the treatment of metastatic NPC.  

Commercial Support Disclosure: This program is supported by an educational grant from Coherus BioSciences.

This activity is free of charge.

Release Date: March 19, 2024 -- Expiration Date: March 19, 2025

Faculty: Deborah J.L. Wong, MD


Faculty introduction and disclosures  

Overview of Nasopharyngeal Carcinoma

  • Epidemiology and global distribution 
  • Pathophysiology 
  • Prognostic considerations and risk factors for distant metastasis 
  • Burden of disease (localized vs metastatic) 

Treatment of Advanced Nasopharyngeal Carcinoma

  • Goals of therapy (palliation, improved failure-free and overall survival) 
  • Treatment considerations, including recent guideline-based approaches 
    • Combination chemotherapy 
      • Gemcitabine/cisplatin 
      • Alternative options 
    • Addition of first-line immunotherapy 
    • Immunotherapy for recurrent or metastatic disease 
    • Immunotherapy for high tumor mutational burden 
    • Extrapolation of data for anti-PD-1 therapies 
  • Patient-specific factors to consider when individualizing therapy, including previous therapy (if recurrent disease) 
  • Investigational agents 
    • Novel agents 
    • Novel combinations 
  • Management of symptoms, adverse effects, and complications during disease course 
  • Multidisciplinary team approach: 
    • Structure, role, and impact 
    • Considerations for RT in advanced disease  
  • Putting it all together: patient case(s) 

Summary, conclusions, and best practice recap  

Learning Objectives

By the end of the session the participant will be able to:

  • Recall the new and emerging treatment options for advanced NPC and how to assess risk factors, prognosis, treatment response, and toxicity.
  • Describe the symptomatic and treatment-related adverse effects associated with metastatic NPC and how to manage them.
  • Define the role and importance of a multidisciplinary approach in caring for patients with advanced NPC.
  • Formulate a treatment plan for a patient with metastatic NPC.


ACCME Activity #202633471

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through ScientiaCME. ScientiaCME is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation: ScientiaCME designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ toward the AMA Physician's Recognition Award. Physicians should only claim credit commensurate with the extent of their participation in the activity.


ABIM MOC Recognition Statement: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

ABIM MOC Credit Type: Medical Knowledge

Physicians: For maintenance of certification (MOC) points, you must enter your board certification ID # and birth date correctly.  It is the learner's responsibility to provide this information completely and accurately at the completion of the activity. Without providing it, the learner will NOT receive MOC points for this activity. By providing this data, you acknowledge that it will be shared with ACCME and the applicable certifying board. Please note: Not all activities on this site provide MOC points. If this activity does not specify that it provides MOC points in this section, then it does NOT provide MOC points. This activity provides MOC points only for ABIM.


ScientiaCME is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hours  of continuing pharmacy education credit. Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit. ACPE #0574-0000-24-006-H01-P. This is an Application (A)-type activity. 

PharmacistsYou must enter your NABP # and birth date correctly so that proof of participation can be posted to your NABP CPE profile. It is the learner's responsibility to provide this information completely and accurately at the completion of the activity. Without providing it, the learner will NOT receive CPE credit for this activity.

Nurses: The American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME. This activity is designated for up to 1.0 AMA PRA Category 1 Credit(s)™.

Physician Assistants: The American Academy of Physician Assistants (AAPA) accepts AMA PRA Category 1 Credit™ assigned by organizations accredited by the ACCME as satisfying Category 1 CME for National Commission on Certification of Physician Assistants (NCCPA) national certification maintenance. This activity is designated for up to 1.0 AMA PRA Category 1 Credit(s)™.

Nurse Practitioners: The American Academy of Nurse Practitioners Certification Board (AANPCB) states that continuing education providers accredited by the ACCME may provide acceptable, accredited Advanced Practice Provider content. This activity is designated for up to 1.0 AMA PRA Category 1 Credit(s)™.

Faculty Disclosure and Resolution of COI

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review by ScientiaCME.

Disclosure of Faculty: Deborah J.L. Wong, MD, HS Associate Clinical Professor, Medicine, David Geffen School of Medicine at UCLA, has received financial compensation from Merck and Regeneron for consulting and AstraZeneca/MedImmune, Bicara Therapeutics, Bristol Myers Squibb, Checkmate Pharmaceuticals, Flamingo Pharma, Genentech, Gilead Sciences, Hookipa Biotech, invoX Pharma, Kura Oncology, Eli Lilly, Merck, Pfizer, Regeneron, TopAlliance BioSciences for grants/research support.

Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.

Faculty WILL NOT discuss off-label uses of a commercial product.

All relevant financial relationships have been mitigated.

ScientiaCME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Commercial Support Disclosure: This program is supported by an educational grant from Coherus BioSciences. 


  • Read the learning objectives above
  • Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
  • View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
  • Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
  • Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural/Linguistic Competence & Health Disparities

System Requirements

Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh

*Required to view Printable PDF Version

Perform Pre-Test (optional)

Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.

Additional Courses That Are Related To This Activity

Advanced systemic mastocytosis: from recognition to treatment

Contemporary treatment approaches in the management of graft-versus-host disease (GVHD)

Advanced hepatocellular carcinoma (HCC) including updates from the European Society for Medical Oncology (ESMO) 2023 and other recent society meetings

The roadmap to optimizing geographic atrophy care: updates in risk assessment, treatment, and care pathways in late-stage age-related macular degeneration